From SpaceX and Saudi Aramco to Alibaba, European privatisations and Switzerland’s largest flotations: a global short history of stock-market debuts, and the lessons for long-term investors. 13 November 2026 In June 2026, SpaceX changed the meaning of a “mega-IPO”. The company sold approximately 555.6 million shares at USD 135 each, raising USD 75 billion before […]
Author: serumbach
Peptides have become one of the most fashionable categories in longevity medicine, but the same name covers prescription medicines with substantial clinical evidence, ordinary nutritional supplements, cosmetic products and experimental compounds whose safety and effectiveness remain uncertain. For Swiss and European consumers, understanding those differences is more important than choosing the most fashionable molecule. In […]
Glycine is an ordinary building block of human biology that has become increasingly popular in longevity routines. Its low price makes supplementation accessible, but the evidence for better sleep, recovery and healthy ageing deserves closer examination. In the rapidly expanding longevity market, a supplement does not necessarily need to be expensive or exotic to become […]
A case study for individual investors who can wait, but still need a defensible price, enforceable rights and a route to repayment. Distressed investing appeals to people who can look beyond a damaged reputation and wait for value to emerge. A failed company can leave cash, investments, receivables and legal claims worth recovering. An original […]
What BlackRock did, who retains the recovery rights, and how an individual investor should assess frozen securities. A security marked at zero can attract a patient investor for understandable reasons. The underlying business may still operate, institutions may prefer to remove an awkward position, and someone investing their own money may be able to wait […]
Creatine occupies an unusual position in the supplement market. It is inexpensive, naturally present in the human body and in ordinary foods, has been studied for decades, and has considerably stronger evidence for a specific benefit than most products sold beside it. Yet the same basic white powder is now marketed as a bodybuilding supplement, […]
From stock-market transactions and confidential information to preferential deals, private investments and market-moving decisions — how politicians, central bankers and public officials can gain financial advantages unavailable to ordinary investors. In June 2017, US Congressman Christopher Collins received confidential information that a biotechnology company in which he was a major shareholder had suffered a serious […]
The acquisition of Credit Suisse has made UBS easier to describe with superlatives, but considerably more difficult to understand through any single statistic. The combined institution is simultaneously Switzerland’s dominant universal bank, one of the world’s largest wealth managers, an important asset manager, a major corporate lender and service provider to the Swiss economy, and […]
A diversified portfolio can still depend on one legal and custody infrastructure. Here is how Swiss investors can think about that hidden concentration without building an unnecessarily complicated offshore structure. Modern investors have become very good at diversifying what they see. A single global ETF can provide exposure to thousands of companies across dozens of […]
From targeted technology restrictions to severe market fragmentation: the same Chinese company can carry very different risks depending on whether it is held as an ADR, Hong Kong share, A-share or ETF The obvious reaction to the Sberbank experience is to ask whether China could one day present the same problem. It is also the […]